J0133Acyclovir injection
Published CMS Medicare Part B payment-limit context for J0133, with recent quarterly history and calculated package-level strength context from the CMS crosswalk.
CMS payment limit
$0.035
per 5 MG · Medicare Part B
Up 105.9%from $0.017 in 2026-Q2
- Current quarter
- Billing unit
Payment limit over time
$0.1333$0.0027
2024-Q4: $0.026; 2025-Q1: $0.051; 2025-Q2: $0.035; 2025-Q3: $0.029; 2025-Q4: $0.037; 2026-Q1: $0.119; 2026-Q2: $0.017; 2026-Q3: $0.035
No current FDA shortage matchThe latest completed FDA data has no affected record matching the Acyclovir Sodium ingredient family (FDA data as of August 20, 2026).
Acyclovir Sodium
Package figures are calculated from the CMS per-unit payment limit × billable units per package; they are not CMS-published package-level payment limits.
Put another code on your radar.
Browse the CMS directory for published payment-limit context across drugs, NDCs, and source-backed HCPCS Level II drug codes.